Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer

Research output: Contribution to journalReview articlepeer-review

83 Scopus citations

Abstract

OBJECTIVE. Neoadjuvant chemotherapy is becoming the standard of care for patients with locally advanced breast cancer. Conventional imaging modalities used for the assessment of tumor response to neoadjuvant chemotherapy rely on changes in size or morphologic characteristics and, therefore, are inherently limited. CONCLUSION. Functional imaging technologies evaluate vascular, metabolic, biochemical, and molecular changes in cancer cells and have a unique ability to detect specific biologic tumor markers, assess therapeutic targets, predict early response to neoadjuvant chemotherapy, and guide individualized cancer therapy.

Original languageEnglish (US)
Pages (from-to)290-299
Number of pages10
JournalAmerican Journal of Roentgenology
Volume208
Issue number2
DOIs
StatePublished - Feb 2017

Keywords

  • Breast MRI
  • Breast PET
  • Breast cancer
  • Molecular breast imaging
  • Neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer'. Together they form a unique fingerprint.

Cite this